Retatrutide

Retatrutide is a first-in-class triple hormone receptor agonist by Eli Lilly, simultaneously activating GLP-1, GIP, and glucagon receptors to maximize appetite suppression, energy expenditure, and hepatic fat reduction through complementary mechanisms. In the Phase 3 TRIUMPH-4 trial, retatrutide 12mg achieved 28.7% mean body weight reduction over 68 weeks, with 82% liver fat reduction observed in MASH phase 2 studies and normalization of hepatic steatosis in 86% of participants at the highest dose. Its distinctive advantage is triple-pathway synergy delivering the most profound weight loss and metabolic improvements observed to date in clinical trials for obesity.

50mg